Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Modifiable factors influencing relapses and disability in multiple sclerosis.
A growing body of literature indicates that the natural course of multiple sclerosis can be influenced by a number of factors. Strong evidence suggests that relapses can be triggered by infections, the postpartum period and stressful life events. Vaccinations against influenza, hepatitis B and tetanus appear to be safe. Surgery, general and epidural anaesthesia, and physical trauma are not asso...
متن کاملImpairment, disability and fatigue in multiple sclerosis
Background: Identifying the predictors of pain is important for both health professionals and researchers, because pain has repeatedly been found to be a strong predictor of activity limitations and participation restrictions. The objective of this study was to determine the predictors of pain presence and severity in a large, well-designed sample of community dwelling individuals with multip...
متن کاملDefining secondary progressive multiple sclerosis.
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis,...
متن کاملModifying disability in progressive multiple sclerosis
www.thelancet.com Vol 383 June 28, 2014 2189 Multiple sclerosis is the most common cause of chronic neurological disability in young adults in developed countries and seems to be increasing in frequency. Disease presentation in 80–90% of patients follows an initial phase characterised by bouts of relapsingremitting neurological dysfunction. These relapses are thought to represent focal areas of...
متن کاملSpotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs. Compared to fingolimod (ie, precursor of the S1P modulators commercially available for the treatment of relapsing-remittin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal
سال: 2020
ISSN: 1352-4585,1477-0970
DOI: 10.1177/1352458520971819